Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays

Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed death-1 (PD-1) checkpoint inhibitor efficacy. Since June 2018, a positive PD-L1 status is required for atezolizumab or pembrolizumab treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Schwamborn, Kristina (VerfasserIn) , Lasitschka, Felix (VerfasserIn) , Schirmacher, Peter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2 July 2019
In: Virchows Archiv
Year: 2019, Jahrgang: 475, Heft: 5, Pages: 599-608
ISSN:1432-2307
DOI:10.1007/s00428-019-02610-z
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00428-019-02610-z
Volltext
Verfasserangaben:Kristina Schwamborn, Johannes U. Ammann, Ruth Knüchel, Arndt Hartmann, Gustavo Baretton, Felix Lasitschka, Peter Schirmacher, Till Braunschweig, Robert Tauber, Franziska Erlmeier, Stefanie Hieke-Schulz, Wilko Weichert

MARC

LEADER 00000caa a2200000 c 4500
001 1689863501
003 DE-627
005 20230427014438.0
007 cr uuu---uuuuu
008 200212s2019 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00428-019-02610-z  |2 doi 
035 |a (DE-627)1689863501 
035 |a (DE-599)KXP1689863501 
035 |a (OCoLC)1341303994 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Schwamborn, Kristina  |d 1976-  |e VerfasserIn  |0 (DE-588)13043745X  |0 (DE-627)501474439  |0 (DE-576)29819547X  |4 aut 
245 1 0 |a Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays  |c Kristina Schwamborn, Johannes U. Ammann, Ruth Knüchel, Arndt Hartmann, Gustavo Baretton, Felix Lasitschka, Peter Schirmacher, Till Braunschweig, Robert Tauber, Franziska Erlmeier, Stefanie Hieke-Schulz, Wilko Weichert 
246 3 0 |a one 
264 1 |c 2 July 2019 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 12.02.2020 
520 |a Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed death-1 (PD-1) checkpoint inhibitor efficacy. Since June 2018, a positive PD-L1 status is required for atezolizumab or pembrolizumab treatment of patients with advanced or metastasized urothelial bladder cancer, who are ineligible for cisplatin-containing therapy. We examined technical comparability and inter-reader agreement of four clinically developed PD-L1 assays in locally advanced disease. Archived, formalin-fixed, paraffin-embedded sections from 30 patients (73.3% cystectomies, 26.7% transurethral resections) were stained by PD-L1 immunohistochemistry using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28-8 at two sites per manufacturers’ protocols and scored blinded at five sites for PD-L1 expression on IC (% per tumor area) and TC (%). Small, non-significant inter-assay differences were observed for IC. For TC, SP142 showed significantly lower staining percentages. Pairwise comparisons revealed − 0.3 to 1.6% differences in adjusted means between assays for IC, and for TC, − 10.5 to − 7.8% (SP142 versus others) and − 1.9 to 2.7% (other comparisons). Inter-reader and inter-assay agreement was moderate to high for both IC and TC. Allocation to binary cutoffs (1%, 5%, 10%) showed substantial to high Kappa agreement scores (0.440-0.923) for IC and TC between assays for each reader. This first multicenter study, with five independent readers blinded with respect to the assay used, suggests that all four currently clinically relevant assays are analytically similar for evaluation of PD-L1-stained IC and three (SP263, 22C3, and 28-8) for PD-L1-stained TC. Inter-observer agreement for trained readers in scoring of both IC and TC positivity was generally high. 
700 1 |a Lasitschka, Felix  |d 1979-  |e VerfasserIn  |0 (DE-588)140496343  |0 (DE-627)618903542  |0 (DE-576)318526077  |4 aut 
700 1 |a Schirmacher, Peter  |d 1961-  |e VerfasserIn  |0 (DE-588)1020440112  |0 (DE-627)691221197  |0 (DE-576)360427448  |4 aut 
773 0 8 |i Enthalten in  |t Virchows Archiv  |d Berlin : Springer, 1847  |g 475(2019), 5, Seite 599-608  |h Online-Ressource  |w (DE-627)254910645  |w (DE-600)1463276-7  |w (DE-576)074754416  |x 1432-2307  |7 nnas  |a Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays 
773 1 8 |g volume:475  |g year:2019  |g number:5  |g pages:599-608  |g extent:10  |a Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays 
856 4 0 |u https://doi.org/10.1007/s00428-019-02610-z  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20200212 
993 |a Article 
994 |a 2019 
998 |g 1020440112  |a Schirmacher, Peter  |m 1020440112:Schirmacher, Peter  |d 910000  |d 912000  |e 910000PS1020440112  |e 912000PS1020440112  |k 0/910000/  |k 1/910000/912000/  |p 7 
998 |g 140496343  |a Lasitschka, Felix  |m 140496343:Lasitschka, Felix  |d 910000  |d 912000  |e 910000PL140496343  |e 912000PL140496343  |k 0/910000/  |k 1/910000/912000/  |p 6 
999 |a KXP-PPN1689863501  |e 3593778629 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1689863501","name":{"displayForm":["Kristina Schwamborn, Johannes U. Ammann, Ruth Knüchel, Arndt Hartmann, Gustavo Baretton, Felix Lasitschka, Peter Schirmacher, Till Braunschweig, Robert Tauber, Franziska Erlmeier, Stefanie Hieke-Schulz, Wilko Weichert"]},"origin":[{"dateIssuedDisp":"2 July 2019","dateIssuedKey":"2019"}],"id":{"doi":["10.1007/s00428-019-02610-z"],"eki":["1689863501"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"10 S."}],"language":["eng"],"title":[{"title_sort":"Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays","title":"Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays"}],"person":[{"role":"aut","given":"Kristina","family":"Schwamborn","display":"Schwamborn, Kristina"},{"display":"Lasitschka, Felix","role":"aut","given":"Felix","family":"Lasitschka"},{"display":"Schirmacher, Peter","given":"Peter","role":"aut","family":"Schirmacher"}],"relHost":[{"titleAlt":[{"title":"Archiv für pathologische Anatomie und Physiologie und für klinische Medicin"},{"title":"Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin"},{"title":"Virchows Archiv / A"}],"note":["Gesehen am 06.12.05"],"pubHistory":["1.1847 -"],"part":{"year":"2019","issue":"5","extent":"10","text":"475(2019), 5, Seite 599-608","pages":"599-608","volume":"475"},"title":[{"title_sort":"Virchows Archiv","subtitle":"official journal of the European Society of Pathology","title":"Virchows Archiv"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"European Society of Pathology","role":"isb"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Berlin ; Heidelberg","dateIssuedDisp":"1847-","publisher":"Springer","dateIssuedKey":"1847"}],"id":{"eki":["254910645"],"issn":["1432-2307"],"zdb":["1463276-7"]},"recId":"254910645","disp":"Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assaysVirchows Archiv"}],"note":["Gesehen am 12.02.2020"]} 
SRT |a SCHWAMBORNMULTICENTR2201